Differential effects of mycophenolate mofetil and cyclosporine A on peripheral blood and cord blood natural killer cells activated with interleukin-2

Cytotherapy

Volumn 16, Issue 10, 2014, Pages 1409-1418

  Derniame, Sophie ^a   Perazzo, Juliana ^a   Lee, Fuiyee ^a   Domogala, Anna ^a   Escobedo Cousin, Michelle ^a   Alnabhan, Rehab ^a   Luevano, Martha ^a   Pedroza Pacheco, Isabela ^a   Cooper, Nichola ^b   Madrigal, Alejandro ^a   Saudemont, Aurore ^a  

^a ANTHONY NOLAN RESEARCH INSTITUTE   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Cord blood; Cyclosporine A; Mycophenolate mofetil; Natural killer cells

Indexed keywords

CYCLOPHILIN; CYCLOSPORIN A; INTERLEUKIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEPTIDES AND PROTEINS; PERFORIN; PROTEIN IMPDH1; PROTEIN IMPDH2; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; CYCLOSPORIN; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID;

ADULT; ARTICLE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; DEGRANULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; NATURAL KILLER CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UMBILICAL CORD BLOOD; ANALOGS AND DERIVATIVES; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; FEMALE; FETUS BLOOD; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; NEWBORN; PREGNANCY;

ADULT; CELLS, CULTURED; CYCLOSPORINE; FEMALE; FETAL BLOOD; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT, NEWBORN; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MYCOPHENOLIC ACID; PREGNANCY;

EID: 84908544740     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2014.05.010     Document Type: Article

References (27)

1. Copelan E.A. Hematopoietic stem-cell transplantation. NEngl J Med 2006, 354:1813-1826.
2. Brunstein C.G., Weisdorf D.J. Future of cord blood for oncology uses. Bone Marrow Transplant 2009, 44:699-707.
3. Brown J.A., Boussiotis V.A. Umbilical cord blood transplantation: basic biology and clinical challenges to immune reconstitution. Clin Immunol 2008, 127:286-297.
4. Holler E. Risk assessment in haematopoietic stem cell transplantation: GvHD prevention and treatment. Best Pract Res Clin Haematol 2007, 20:281-294.
5. Ho V.T., Cutler C. Current and novel therapies in acute GVHD. Best Pract Res Clin Haematol 2008, 21:223-237.
6. Zeiser R., Marks R., Bertz H., Finke J. Immunopathogenesis ofacute graft-versus-host disease: implications for novel preventive and therapeutic strategies. Ann Hematol 2004, 83:551-565.
7. Osunkwo I., Bessmertny O., Harrison L., Cheung Y.K., Van de Ven C., del Toro G., et al. Apilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. Biol Blood Marrow Transplantation 2004, 10:246-258.
8. Alousi A.M., Weisdorf D.J., Logan B.R., Bolanos-Meade J., Carter S., Difronzo N., et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009, 114:511-517.
9. Nieto Y., Patton N., Hawkins T., Spearing R., Bearman S.I., Jones R.B., et al. Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation. Biol Blood Marrow Transplant 2006, 12:217-225.
10. Jacobson P., Rogosheske J., Barker J.N., Green K., Ng J., Weisdorf D., et al. Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. Clin Pharmacol Ther 2005, 78:486-500.
11. Shevach E.M. The effects of cyclosporin A on the immune system. Annu Rev Immunol 1985, 3:397-423.
12. Schreiber S.L., Crabtree G.R. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992, 13:136-142.
13. Flanagan W.M., Corthesy B., Bram R.J., Crabtree G.R. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 1991, 352:803-807.
14. Rao A., Luo C., Hogan P.G. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 1997, 15:707-747.
15. Bolwell B., Sobecks R., Pohlman B., Andresen S., Rybicki L., Kuczkowski E., et al. Aprospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004, 34:621-625.
16. Neumann F., Graef T., Tapprich C., Vaupel M., Steidl U., Germing U., et al. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant 2005, 35:1089-1093.
17. Nash R.A., Johnston L., Parker P., McCune J.S., Storer B., Slattery J.T., et al. Aphase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2005, 11:495-505.
18. Perez-Simon J.A., Martino R., Caballero D., Valcarcel D., Rebollo N., de la Camara R., et al. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 2008, 14:664-671.
19. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
20. Ohata K., Espinoza J.L., Lu X., Kondo Y., Nakao S. Mycophenolic acid inhibits natural killer cell proliferation and cytotoxic function: a possible disadvantage of including mycophenolate mofetil in the graft-versus-host disease prophylaxis regimen. Biol Blood Marrow Transplant 2011, 17:205-213.
21. Wai L.E., Fujiki M., Takeda S., Martinez O.M., Krams S.M. Rapamycin, but not cyclosporine or FK506, alters natural killer cell function. Transplantation 2008, 85:145-149.
22. Wang H., Grzywacz B., Sukovich D., McCullar V., Cao Q., Lee A.B., et al. The unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations. Blood 2007, 110:1530-1539.
23. Lin S.J., Kuo M.L. Effect of cyclosporin A on interleukin-15-activated umbilical cord blood natural killer cell function. Cytotherapy 2008, 10:397-405.
24. Derniame S., Lee F., Domogala A., Madrigal A., Saudemont S. Unique effects of mycophenolate mofetil on cord blood T cells: implications for GVHD prophylaxis. Transplantation 2014, 97:870-878.
25. Luevano M., Daryouzeh M., Alnabhan R., Querol S., Khakoo S., Madrigal A., et al. The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation. Hum Immunol 2012, 73:248-257.
26. Eissens D.N., Van Der Meer A., Van Cranenbroek B., Preijers F.W., Joosten I. Rapamycin and MPA, but not CsA, impair human NK cell cytotoxicity due to differential effects on NK cell phenotype. Am J Transplant 2010, 10:1981-1990.
27. Shapira M.Y., Hirshfeld E., Weiss L., Zeira M., Kasir J., Or R., et al. Mycophenolate mofetil does not suppress the graft-versus-leukemia effect or the activity of lymphokine-activated killer (LAK) cells in a murine model. Cancer Immunol Immunother 2005, 54:383-388.